Cover Image

Loss or inhibition of stromal-derived PlGF prolongs survival of mice with imatinib-resistant Bcr-Abl1+ Leukemia

Imatinib has revolutionized the treatment of Bcr-Abl1+ chronic myeloid leukemia (CML), but, in most patients, some leukemia cells persist despite continued therapy, while others become resistant. Here, we report that PlGF levels are elevated in CML and that PlGF produced by bone marrow stromal cells...

Full description

Saved in:
Bibliographic Details
Main Authors: Schmidt, Thomas (Author) , Masouleh, Behzad Kharabi (Author) , Loges, Sonja (Author) , Cauwenberghs, Sandra (Author) , Fraisl, Peter (Author) , Maes, Christa (Author) , Jonckx, Bart (Author) , De Keersmaecker, Kim (Author) , Kleppe, Maria (Author) , Tjwa, Marc (Author) , Schenk, Thomas (Author) , Vinckier, Stefan (Author) , Fragoso, Rita (Author) , De Mol, Maria (Author) , Beel, Karolien (Author) , Dias, Sérgio (Author) , Verfaillie, Catherine (Author) , Clark, Richard E. (Author) , Brümmendorf, Tim H. (Author) , Vandenberghe, Peter (Author) , Rafii, Shahin (Author) , Holyoake, Tessa (Author) , Hochhaus, Andreas (Author) , Cools, Jan (Author) , Karin, Michael (Author) , Carmeliet, Geert (Author) , Dewerchin, Mieke (Author) , Carmeliet, Peter (Author)
Format: Article (Journal)
Language:English
Published: 13 June 2011
In: Cancer cell
Year: 2011, Volume: 19, Issue: 6, Pages: 740-753
ISSN:1878-3686
DOI:10.1016/j.ccr.2011.05.007
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.ccr.2011.05.007
Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S1535610811001656
Get full text
Author Notes:Thomas Schmidt, Behzad Kharabi Masouleh, Sonja Loges, Sandra Cauwenberghs, Peter Fraisl, Christa Maes, Bart Jonckx, Kim De Keersmaecker, Maria Kleppe, Marc Tjwa, Thomas Schenk, Stefan Vinckier, Rita Fragoso, Maria De Mol, Karolien Beel, Sérgio Dias, Catherine Verfaillie, Richard E. Clark, Tim H. Brümmendorf, Peter Vandenberghe, Shahin Rafii, Tessa Holyoake, Andreas Hochhaus, Jan Cools, Michael Karin, Geert Carmeliet, Mieke Dewerchin, and Peter Carmeliet
Description
Summary:Imatinib has revolutionized the treatment of Bcr-Abl1+ chronic myeloid leukemia (CML), but, in most patients, some leukemia cells persist despite continued therapy, while others become resistant. Here, we report that PlGF levels are elevated in CML and that PlGF produced by bone marrow stromal cells (BMSCs) aggravates disease severity. CML cells foster a soil for their own growth by inducing BMSCs to upregulate PlGF, which not only stimulates BM angiogenesis, but also promotes CML proliferation and metabolism, in part independently of Bcr-Abl1 signaling. Anti-PlGF treatment prolongs survival of imatinib-sensitive and -resistant CML mice and adds to the anti-CML activity of imatinib. These results may warrant further investigation of the therapeutic potential of PlGF inhibition for (imatinib-resistant) CML.
Item Description:Gesehen am 13.10.2022
Physical Description:Online Resource
ISSN:1878-3686
DOI:10.1016/j.ccr.2011.05.007

Similar Items